CREATIVE MEDICAL TECHNOLOGY (CELZ)

US22529Y4089 - Common Stock

5.21  +0.06 (+1.17%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CELZ. CELZ was compared to 592 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CELZ as it has an excellent financial health rating, but there are worries on the profitability. CELZ is quite expensive at the moment. It does show a decent growth rate.



1

1. Profitability

1.1 Basic Checks

In the past year CELZ has reported negative net income.
CELZ had a negative operating cash flow in the past year.
In the past 5 years CELZ reported 4 times negative net income.
In the past 5 years CELZ always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -78.50%, CELZ is doing worse than 72.79% of the companies in the same industry.
CELZ has a Return On Equity (-81.22%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -78.5%
ROE -81.22%
ROIC N/A
ROA(3y)-1642.74%
ROA(5y)-1874.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

CELZ has a Gross Margin of 33.33%. This is in the better half of the industry: CELZ outperforms 77.21% of its industry peers.
In the last couple of years the Gross Margin of CELZ has declined.
CELZ does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 33.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.89%
GM growth 5YN/A

8

2. Health

2.1 Basic Checks

CELZ does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CELZ has been increased compared to 1 year ago.
CELZ has more shares outstanding than it did 5 years ago.
CELZ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 2.17 indicates that CELZ is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of CELZ (2.17) is better than 68.37% of its industry peers.
CELZ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.17
ROIC/WACCN/A
WACC8.98%

2.3 Liquidity

CELZ has a Current Ratio of 28.67. This indicates that CELZ is financially healthy and has no problem in meeting its short term obligations.
CELZ's Current ratio of 28.67 is amongst the best of the industry. CELZ outperforms 97.28% of its industry peers.
CELZ has a Quick Ratio of 28.64. This indicates that CELZ is financially healthy and has no problem in meeting its short term obligations.
CELZ has a better Quick ratio (28.64) than 97.28% of its industry peers.
Industry RankSector Rank
Current Ratio 28.67
Quick Ratio 28.64

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 83.08% over the past year.
Looking at the last year, CELZ shows a very negative growth in Revenue. The Revenue has decreased by -80.00% in the last year.
CELZ shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -19.10% yearly.
EPS 1Y (TTM)83.08%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-45.71%
Revenue 1Y (TTM)-80%
Revenue growth 3Y-19.1%
Revenue growth 5YN/A
Revenue growth Q2Q-83.33%

3.2 Future

CELZ is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.94% yearly.
Based on estimates for the next years, CELZ will show a very strong growth in Revenue. The Revenue will grow by 147.51% on average per year.
EPS Next Y61.7%
EPS Next 2Y23.25%
EPS Next 3Y16.13%
EPS Next 5Y19.94%
Revenue Next Year-98.61%
Revenue Next 2Y-41.42%
Revenue Next 3Y17.34%
Revenue Next 5Y147.51%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CELZ. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CELZ. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as CELZ's earnings are expected to grow with 16.13% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.25%
EPS Next 3Y16.13%

0

5. Dividend

5.1 Amount

No dividends for CELZ!.
Industry RankSector Rank
Dividend Yield N/A

CREATIVE MEDICAL TECHNOLOGY

NASDAQ:CELZ (3/28/2024, 4:30:00 PM)

5.21

+0.06 (+1.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap7.19M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -78.5%
ROE -81.22%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 33.33%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 28.67
Quick Ratio 28.64
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)83.08%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y61.7%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-80%
Revenue growth 3Y-19.1%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y